Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?  

In these situations, adjuvant AC should be considered. Anthracyclines have been shown to improve outcomes in high-risk TNBC in the adjuvant setting across multiple trials. CREATE-X used adjuvant capecitabine in patients who had residual disease after neoadjuvant anthracyclines and taxanes. It wasn't...